A single-center, single-arm, open-label, multi-dose, three-period study was conducted in healthy Chinese volunteers.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
12
Hydrochlorothiazide and Henagliflozin Proline
Shanghai Xuhui Central Hospital
Shanghai, Shanghai Municipality, China
Steady-state pharmacokinetics parameters of Henagliflozin Proline: AUCτ,ss
Time frame: Day 10, Day 14
Steady-state pharmacokinetics parameters of Henagliflozin Proline: Css, max
Time frame: Day 10, Day 14
Steady-state pharmacokinetics parameters of Hydrochlorothiazide: AUCτ,ss
Time frame: Day 4, Day 14
Steady-state pharmacokinetics parameters of Hydrochlorothiazide: Css, max
Time frame: Day 4, Day 14
Pharmacokinetics parameters of Henagliflozin Proline: Tmax
Time frame: Day 10, Day 14
Pharmacokinetics parameters of Henagliflozin Proline: t1/2
Time frame: Day 10, Day 14
Pharmacokinetics parameters of Henagliflozin Proline: CL/F
Time frame: Day 10, Day 14
Pharmacokinetics parameters of Hydrochlorothiazide: Tmax
Time frame: Day 4, Day 14
Pharmacokinetics parameters of Hydrochlorothiazide: t1/2
Time frame: Day 4, Day 14
Pharmacokinetics parameters of Hydrochlorothiazide: CL/F
Time frame: Day 4, Day 14
Accumulated urine electrolyte excretion 24 hours after administration
Time frame: Day 4, Day 14
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Urinary volume at 24 hours after administration
Time frame: Day 4, Day 10, Day 14
Accumulated urine glucose excretion within 24 hours after administration
Time frame: Day 10, Day 14
Adverse events
Time frame: Day 4, Day 14